- Medicine Name: Saphnelo
- Generic Name: Anifrolumab-fnia
- Dosage Form & Strength: Injection: 300 mg/2 mL (150 mg/mL) in a single-dose vial
- Manufactured By: AstraZeneca
Saphnelo (anifrolumab-fnia) is a type I interferon (IFN) receptor antagonist used to treat adults with moderate to severe systemic lupus erythematosus (SLE), who are taking other lupus drugs, regardless of race or ethnicity standard therapy.
Recommended Dosage: Saphnelo is supplied as a single-dose vial. It must be diluted before intravenous administration. The recommended dosage regimen of Saphnelo injection is 300 mg, administered as an intravenous infusion over a 30-minute time span, every 4 weeks.
If a planned/scheduled infusion of Saphnelo is missed, administer it as promptly as possible. A minimum interval of 14 days between infusions should be maintained.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.